Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03564340
Title Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Platinum-Resistant Ovarian Cancer
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors Regeneron Pharmaceuticals

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer


Cemiplimab + REGN4018


Age Groups: adult | senior
Covered Countries USA | BEL

No variant requirements are available.